WGS — GeneDx Holdings Corp
NASDAQ · Health Care · Health Care
- Latest Close
- $68.1
- 30-Day Move
- -55.1%
- Market Cap
- $2.3B
- Shares Outstanding
- 29,290,000
- P/B Ratio
- 12.2
- ROE
- -6.8%
Analyst consensus: Buy · 13 analysts
GeneDx Holdings Corp
A read-only Alphactor snapshot forGeneDx Holdings Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$68.1
30-Day Move
-55.1%
Market Cap
$2.3B
Shares Outstanding
29,290,000
P/B Ratio
12.2
ROE
-6.8%
$68.10
-55.1%last 90 delayed daily bars
90D High
$157.15
90D Low
$55.18
Avg Volume
694,599
Gross margin is running at 69.7%, which gives a quick read on operating quality before you open the full model.
Net margin is -4.9%, useful for comparing WGS against peers in Health Care.
WGS is down 55.1% over the last 30 trading days shown on this page.
Latest operating income is $-14M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$44.20
Rule of 40
43.3%
Dark Pool Short %
33.1%
Latest Close
$68.1
30-Day Move
-55.1%
Market Cap
$2.3B
Shares Outstanding
29,290,000
P/B Ratio
12.2
ROE
-6.8%
ROA
-4.0%
Gross Margin
69.7%
Operating Margin
-3.1%
Net Margin
-4.9%
Debt / Equity
0.23
Current Ratio
2.46
Latest Revenue
$121M
Revenue
$121M
Gross Profit
$84M
Operating Income
$-14M
Net Income
$-18M
Gross Margin
6974.0%
Net Margin
-492.0%
Current Ratio
2.46
Debt / Equity
0.23
Fair Value
$44.20
Upside / Downside
-35.1%
Signal
Overvalued
Implied Growth
34.8%
DCF
$15.70
EV/Rev
$72.70
Growth Assumption
22.1%
Discount Rate
9.0%
Terminal Growth
2.0%
Base FCF
$14M
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
High growth priced in
Altman Z
3.77
Safe
Piotroski
6
Moderate (4-6)
Cash Conversion
-1.58x
Rule of 40
43.3%
Strong
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $235M | $-458M | $-549M | $-333M |
| 2023-12-31 | $203M | $-170M | $-176M | $-186M |
| 2024-12-31 | $305M | $-23M | $-52M | $-34M |
| 2025-12-31 | $428M | $-13M | $-21M | $14M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| ARK ETF Trust-ARK Innovation ETF | 708,859 | 0.02% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 587,297 | 0.02% | 2025-12-31 |
| Franklin Custodian Funds-FRANKLIN DYNATECH FUND | 500,000 | 0.02% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | 464,815 | 0.02% | 2026-02-28 |
| SmallCap World Fund Inc | 393,150 | 0.01% | 2025-12-31 |
| AIM Counselor Series TRT -Invesco Discovery Fd. | 360,454 | 0.01% | 2025-11-30 |
| HARBOR FUNDS-Harbor Small Cap Growth Fund | 293,193 | 0.01% | 2026-01-31 |
| LORD ABBETT DEVELOPING GROWTH Fd., INC.-Lord Abbett Developing Growth | 280,558 | 0.01% | 2026-01-31 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Qube Research & Technologies
Filed 2025-08-14
--
--
Goldman Sachs
Filed 2026-02-10
$159M
+4.5%
Vanguard Group
Filed 2026-01-29
$155M
+1.6%
FMR LLC (Fidelity)
Filed 2026-02-17
$108M
+65.5%
Invesco
Filed 2026-02-19
$102M
+59.2%
ARK Investment Management
Filed 2026-02-11
$79M
--
Geode Capital Management
Filed 2026-02-09
$66M
+3.1%
4.23
Consensus
Buy—
—
—
13
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.